Skip to Main Content

Author Details

Massimo Gadina
National Institute of Arthritis and Musculoskeletal and Skin Diseases
1988
143
57
PMIDPaper TitleJournal TitlePublished Year
37923366Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.Ann Rheum Dis2024
37923366Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.Ann Rheum Dis2024
38012368Author Correction: Protein kinases: drug targets for immunological disorders.Nat Rev Immunol2024
38007359JAK inhibitors: Is specificity at all relevant?Semin Arthritis Rheum2024
38049983Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.Ann Rheum Dis2024
38012368Author Correction: Protein kinases: drug targets for immunological disorders.Nat Rev Immunol2024
38007359JAK inhibitors: Is specificity at all relevant?Semin Arthritis Rheum2024
38049983Clonal haematopoiesis across the age spectrum of vasculitis patients with Takayasu's arteritis, ANCA-associated vasculitis and giant cell arteritis.Ann Rheum Dis2024
37142918Cell Viability Multiplexing: Quantification of Cellular Viability by Barcode Flow Cytometry and Computational Analysis.Methods Mol Biol2023
37756335Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammation.Proc Natl Acad Sci U S A2023
37681930Identification of Unique microRNA Profiles in Different Types of Idiopathic Inflammatory Myopathy.Cells2023
37142918Cell Viability Multiplexing: Quantification of Cellular Viability by Barcode Flow Cytometry and Computational Analysis.Methods Mol Biol2023
37256972Variant <i>STAT4</i> and Response to Ruxolitinib in an Autoinflammatory Syndrome.N Engl J Med2023
37188939Protein kinases: drug targets for immunological disorders.Nat Rev Immunol2023
37756335Divergent roles for STAT4 in shaping differentiation of cytotoxic ILC1 and NK cells during gut inflammation.Proc Natl Acad Sci U S A2023
37681930Identification of Unique microRNA Profiles in Different Types of Idiopathic Inflammatory Myopathy.Cells2023
37256972Variant <i>STAT4</i> and Response to Ruxolitinib in an Autoinflammatory Syndrome.N Engl J Med2023
37188939Protein kinases: drug targets for immunological disorders.Nat Rev Immunol2023
35168456Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.Expert Rev Clin Immunol2022
36240739The JAK-STAT pathway at 30: Much learned, much more to do.Cell2022
36220328Changes in cardiorespiratory function and fatigue following 12 weeks of exercise training in women with systemic lupus erythematosus: a pilot study.Lupus Sci Med2022
35868845Gain-of-function mutations in <i>ALPK1</i> cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome.Ann Rheum Dis2022
35984892PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes.Sci Immunol2022
35914929Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus.Ann Rheum Dis2022
36643918Editorial: JAK inhibition in autoimmune and inflammatory diseases.Front Immunol2022
35168456Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.Expert Rev Clin Immunol2022
36643918Editorial: JAK inhibition in autoimmune and inflammatory diseases.Front Immunol2022
35868845Gain-of-function mutations in <i>ALPK1</i> cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome.Ann Rheum Dis2022
36240739The JAK-STAT pathway at 30: Much learned, much more to do.Cell2022
35984892PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes.Sci Immunol2022
36220328Changes in cardiorespiratory function and fatigue following 12 weeks of exercise training in women with systemic lupus erythematosus: a pilot study.Lupus Sci Med2022
35914929Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus.Ann Rheum Dis2022
32843325Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.Ann Rheum Dis2021
34180156A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?Arthritis Rheumatol2021
342902433-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine.Nat Commun2021
33950229JAK1: Number one in the family; number one in inflammation?Rheumatology (Oxford)2021
33892719Homozygous variant p. Arg90His in NCF1 is associated with early-onset Interferonopathy: a case report.Pediatr Rheumatol Online J2021
33779074Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.Arthritis Rheumatol2021
34099646Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.Nat Commun2021
33725478Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery.Immunity2021
33930196JAK inhibitors: Ten years after.Eur J Immunol2021
34347289Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver.Eur J Immunol2021
32843325Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.Ann Rheum Dis2021
34625141JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.J Allergy Clin Immunol2021
35056105Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.Pharmaceuticals (Basel)2021
33892719Homozygous variant p. Arg90His in NCF1 is associated with early-onset Interferonopathy: a case report.Pediatr Rheumatol Online J2021
33779074Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.Arthritis Rheumatol2021
33725478Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery.Immunity2021
33930196JAK inhibitors: Ten years after.Eur J Immunol2021
35056105Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.Pharmaceuticals (Basel)2021
  • 1 - 50 of 286

Recommended Authors

Edmond M Linossi
The Walter and Eliza Hall Institute of Medical Research
Career Start Year 2012
Number of shared co-authors 0
Hao Li
Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University
Career Start Year 2011
Number of shared co-authors 0
Huiyuan Zhang
Texas Children's Cancer Center
Career Start Year 2010
Number of shared co-authors 0
Moutih Rafei
Universite de Montreal
Career Start Year 2007
Number of shared co-authors 0
Zhaoqi Yan
University of Illinois College of Medicine Rockford
Career Start Year 2007
Number of shared co-authors 0
Thomas B Sundberg
Cutaneous Biology Research Center
Career Start Year 2006
Number of shared co-authors 2
Aaron M Ring
Yale University School of Medicine
Career Start Year 2006
Number of shared co-authors 0
Jinbo Yang
School of Medicine and Pharmacy, Ocean University of China
Career Start Year 2003
Number of shared co-authors 0
Andrew Wang
Yale University School of Medicine
Career Start Year 2001
Number of shared co-authors 0
Dorian LaTocha
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 1
Sunil K Joshi
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 2
Cristina M Tato
Institute of Immunity, Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 4
Seunghee Kim-Schulze
Icahn School of Medicine at Mount Sinai
Career Start Year 1996
Number of shared co-authors 2
Erik J Peterson
University of California
Career Start Year 1996
Number of shared co-authors 1
Chander Raman
University of Alabama at Birmingham
Career Start Year 1990
Number of shared co-authors 0
Qi Wu
University of Michigan Medical School
Career Start Year 1989
Number of shared co-authors 0
Jami Willette-Brown
Center for Cancer Research, National Cancer Institute
Career Start Year 1989
Number of shared co-authors 1
Kaoru Saijo
Helen Wills Neuroscience Institute, University of California berkeley
Career Start Year 1988
Number of shared co-authors 1
Thomas Decker
University of Vienna
Career Start Year 1985
Number of shared co-authors 0
Yoko Kosaka
Oregon Health & Science University
Career Start Year 1984
Number of shared co-authors 1
Su M Metcalfe
University of Cambridge Clinical School, LIFNanoRx Ltd
Career Start Year 1984
Number of shared co-authors 0
Penelope A Morel
University of Pittsburgh
Career Start Year 1982
Number of shared co-authors 0
Robert E Lewis
University of Nebraska Medical Center
Career Start Year 1980
Number of shared co-authors 0
David E Levy
NYU Grossman School of Medicine
Career Start Year 1979
Number of shared co-authors 2
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 1979
Number of shared co-authors 2
Daniel W McVicar
National Cancer Institute
Career Start Year 1976
Number of shared co-authors 6
Howard A Young
Center for Cancer Research, National Cancer Institute
Career Start Year 1975
Number of shared co-authors 7
Katherine A Siminovitch
University of Toronto, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital
Career Start Year 1974
Number of shared co-authors 2
Tak W Mak
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1970
Number of shared co-authors 4
Giorgio Trinchieri
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1969
Number of shared co-authors 14

Collaborators

John J O'Shea
National Institute of Arthritis, National Institutes of Health
Co-authored papers 56
Wanxia Li Tsai
National Institute of Arthritis
Co-authored papers 27
Daniel L Kastner
Co-authored papers 18
Elaine F Remmers
Co-authored papers 9
Yuka Kanno
Co-authored papers 8
Yasuko Furumoto
Co-authored papers 8
Robert A Colbert
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Co-authored papers 7
Edward W Cowen
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Co-authored papers 6
Sergio D Rosenzweig
National Institute of Allergy and Infectious Diseases
Co-authored papers 6
James C Mullikin
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 5
Alejandro V Villarino
University of Miami Miller School of Medicine
Co-authored papers 4
Richard J Youle
Co-authored papers 4
Laura Santambrogio
Weill Cornell School of Medicine
Co-authored papers 4
Neal S Young
National Heart Lung and Blood Institute Division of Intramural Research
Co-authored papers 4
Theo Heller
National Institute of Diabetes and Digestive and Kidney Diseases
Co-authored papers 4
Joshua D Milner
Columbia University
Co-authored papers 4
Cristina C Clement
Englander Institute for Precision Medicine
Co-authored papers 3
Peter C Grayson
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Co-authored papers 3
Rajesh K Soni
Herbert Irving Comprehensive Cancer Center, Columbia University
Co-authored papers 3
Michele Nehrebecky
National Human Genome Research Institute, National Institutes of Health (NIH)
Co-authored papers 3
Camilo Toro
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 2
Peter K Gregersen
Co-authored papers 2
Stephen M Hewitt
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Benjamin D Korman
Co-authored papers 2
Vittorio Sartorelli
Co-authored papers 2
Kristina I Rother
Co-authored papers 2
Dirk Foell
Co-authored papers 2
Christopher I Amos
Baylor College of Medicine
Co-authored papers 2
Xinghao Wang
Co-authored papers 2
Douglas B Kuhns
Frederick National Laboratory for Cancer Research
Co-authored papers 2
Release 1.2